Grunenthal and partners publish positive data for Nucynta

Pharmaceutical Company Product News

Grunenthal has presented new trial data on the pain relief treatment Nucynta in association with several of its research affiliates.

The company joined PriCara, Ortho-McNeil-Janssen and Johnson and Johnson Pharmaceutical Research and Development in presenting the results at the Annual Scientific Meeting of the American Pain Society.

These phase III trial results showed that the drug caused lower incidence of nausea, vomiting and constipation among elderly patients with low-back or osteoarthritis when compared to oxycodone immediate release tablets.

Dr Gary Vorsanger, Ortho-McNeil Janssen Scientific Affairs, said: "These data help illustrate that Nucynta may be an important treatment option to consider for older patients."

The partners are still awaiting regulatory approval for the drug, with Grunenthal set to take responsibility for marketing the treatment in Europe.

Other pain relief treatments sold by Grunenthal include its Zydol range of products, as well as its Versatis five per cent medicated plaster for use against skin conditions.

See all the latest jobs in Pharmaceutical
Return to news

Tags